This study assesses satisfaction with iron chelation therapy (ICT) based on a reliable and valid instrument, and explores the relationship between satisfaction and adherence to ICT. Patients in the USA and UK completed a new "Satisfaction with ICT" (SICT) instrument consisting of 28 items, three pertaining to adherence. Simple and multivariate regression analyses assessed the relationship between satisfaction with different aspects of ICT and adherence. First assessments of the SICT instrument indicate its validity and reliability. Recommended thresholds for internal consistency, convergent validity, discriminant validity, and floor and ceiling effects were met. A number of variables were identified in the simple linear regression analyses as significant predictors of "never thinking about stopping ICT," a proxy for adherence. These significant variables were entered into the multivariate model to assess the combined factor effects, explaining 42% of the total variance of "never thinking about stopping ICT." A significant and positive relationship was demonstrated between "never thinking about stopping ICT" and age (P = 0.04), Perceived Effectiveness of ICT (P = 0.003), low Burden of ICT (P = 0.002), and low Side Effects of ICT (P = 0.01). The SICT is a reliable and valid instrument which will be useful in ICT clinical trials. Furthermore, the administration of ICT by slow subcutaneous infusion negatively impacts on satisfaction with ICT which was shown to be a determinant of adherence. This points to the need for new more convenient and less burdensome oral iron chelators to increase adherence, and ultimately to improve patient outcomes.
机构:
Rush Univ, Med Ctr, Dept Internal Med, Div Hematol Oncol, Chicago, IL 60612 USARush Univ, Med Ctr, Dept Internal Med, Div Hematol Oncol, Chicago, IL 60612 USA
Shammo, Jamile M.
Komrokji, Rami S.
论文数: 0引用数: 0
h-index: 0
机构:
H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL USARush Univ, Med Ctr, Dept Internal Med, Div Hematol Oncol, Chicago, IL 60612 USA
机构:
Univ Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, MalaysiaUniv Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, Malaysia
Chong, Chia Chee
Redzuan, Adyani Md
论文数: 0引用数: 0
h-index: 0
机构:
Univ Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, MalaysiaUniv Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, Malaysia
Redzuan, Adyani Md
Sathar, Jameela
论文数: 0引用数: 0
h-index: 0
机构:
Hosp Ampang, Hematol Dept, Ampang, Selangor, MalaysiaUniv Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, Malaysia
Sathar, Jameela
Makmor-Bakry, Mohd
论文数: 0引用数: 0
h-index: 0
机构:
Univ Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, MalaysiaUniv Kebangsaan Malaysia, Ctr Qual Management Med, Fac Pharm, Kuala Lumpur 50300, Malaysia
机构:
Capital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R ChinaCapital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R China
Zou, Dong-Mei
Rong, Dong-Dong
论文数: 0引用数: 0
h-index: 0
机构:
Capital Med Univ, Xuanwu Hosp, Dept Radiol, 45 Changchun St, Beijing 100053, Peoples R ChinaCapital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R China
Rong, Dong-Dong
Zhao, Hong
论文数: 0引用数: 0
h-index: 0
机构:
Capital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R ChinaCapital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R China
Zhao, Hong
Su, Li
论文数: 0引用数: 0
h-index: 0
机构:
Capital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R ChinaCapital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R China
Su, Li
Sun, Wan-Ling
论文数: 0引用数: 0
h-index: 0
机构:
Capital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R ChinaCapital Med Univ, Xuanwu Hosp, Dept Hematol, 45 Changchun St, Beijing 100053, Peoples R China
机构:
Harvard Univ, Sch Med, Div Hematol Malignancies, Dana Farber Canc Inst, Boston, MA 02215 USAHarvard Univ, Sch Med, Div Hematol Malignancies, Dana Farber Canc Inst, Boston, MA 02215 USA